Implementing a Cost-Effective Cure for Batch and Sequence Management - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Implementing a Cost-Effective Cure for Batch and Sequence Management

Equipment and Processing Report

Implementing a Cost-Effective Cure for Batch and Sequence Management

Q. Our company wants to upgrade its single-product semiworks facility to a midscale production facility capable of producing a variety of regulated products. How can we implement a flexible solution without increasing our project budget?

A. Other companies in similar situations have implemented flexible, cost-effective solutions. For example, a small-molecule API manufacturer wanted to upgrade its single-product semiworks facility to a midscale production facility capable of producing a variety of products. The company needed a scalable solution that would meet regulatory requirements and increased security demands for producing regulated materials and controlled substances. Unfortunately, the existing control infrastructure was based on a hard-coded control system from the 1990s that limited its ability to quickly and easily adjust programming and production, which was a requirement for the company as it moved the facility to multiproduct production. The company worked with its automation partner to identify the best control solution.

Some modern control systems allow users to program batch sequencing and use the controller independently of application servers and software. This independent function allows companies to avoid costly, engineering-intensive custom code or additional server infrastructure associated with large-scale batch solutions. Software is available to configure recipes and formulas directly in the controller without requiring code changes to the system, which helps streamline the implementation of approved changes.

Companies today would like to reduce their use of manual, paper-based batch sheets for detailed processing instructions, but API manufacturing processes often require a high level of detail. In this company’s process, for example, removing a kill solution that deactivates a volatile chemical too soon could significantly impact the entire process. Automated solutions that take these detailed instructions into account can be embedded directly into the control system, which can improve the quality and consistency of APIs and avoid the delays that naturally occur during manual operations.

—John Párraga, global process technical consultant at Rockwell Automation.

If you have a problem with your equipment or process, an industry expert may have the solution. Please send your question to Jennifer Markarian, editor of Equipment and Processing Report, and we may be able to provide an answer in a future issue. All questions will remain anonymous.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
28%
Oversee medical treatment of patients in the US.
12%
Provide treatment for patients globally.
9%
All of the above.
45%
No government involvement in patient treatment or drug development.
7%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
Source: Equipment and Processing Report,
Click here